Back to top
Inhibrx Biosciences, Inc. (INBX)
(Delayed Data from NSDQ)
$13.83 USD
13.83
178,264
-0.50 (-3.49%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $13.71 -0.12 (-0.87%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
View All Zacks #1 Ranked StocksCash flow Statements
Fiscal Year End for Inhibrx Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|---|
| Cash Flow From Operations, Investments & Financial Activities |
|||||
| Net Income (Loss) | -154.96 | -115.33 | NA | NA | NA |
| Depreciation/Amortization & Depletion | 1.19 | 1.23 | NA | NA | NA |
| Net Change from Assets/Liabilities | 2.31 | 3.86 | NA | NA | NA |
| Net Cash from Discontinued Operations | 0.00 | 0.00 | NA | NA | NA |
| Other Operating Activities | 22.46 | 19.43 | NA | NA | NA |
| Net Cash From Operating Activities | -129.01 | -90.81 | NA | NA | NA |
| Property & Equipment | -4.59 | -0.69 | NA | NA | NA |
| Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | NA | NA | NA |
| Investments | 0.00 | 0.00 | NA | NA | NA |
| Other Investing Activities | 0.00 | 0.00 | NA | NA | NA |
| Net Cash from Investing Activities | -4.59 | -0.69 | NA | NA | NA |
Uses of Funds
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|---|
| Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | NA | NA | NA |
| Issuance (Repayment) of Debt | 0.00 | 0.00 | NA | NA | NA |
| Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | NA | NA | NA |
| Payment of Dividends & Other Distributions | 0.00 | 0.00 | NA | NA | NA |
| Other Financing Activities | 133.60 | 91.50 | NA | NA | NA |
| Net Cash from Financing Activities | 133.60 | 91.50 | NA | NA | NA |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | NA | NA | NA |
| Net Change In Cash & Equivalents | 0.00 | 0.00 | NA | NA | NA |
| Cash at Beginning of Period | 0.00 | 0.00 | NA | NA | NA |
| Cash at End of Period | 0.00 | 0.00 | NA | NA | NA |
| Diluted Net EPS | NA | NA | NA | NA | NA |
Fiscal Year End for Inhibrx Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
| 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|---|
| Cash Flow From Operations, Investments & Financial Activities |
|||||
| Net Income (Loss) | NA | 1,779.30 | -49.27 | -154.96 | NA |
| Depreciation/Amortization & Depletion | NA | 0.84 | 0.36 | 1.19 | NA |
| Net Change from Assets/Liabilities | NA | 42.69 | 3.09 | 2.31 | NA |
| Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | NA |
| Other Operating Activities | NA | -1,943.23 | 5.51 | 22.46 | NA |
| Net Cash From Operating Activities | NA | -120.41 | -40.31 | -129.01 | NA |
| Property & Equipment | NA | -2.33 | -1.12 | -4.59 | NA |
| Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | NA |
| Investments | NA | 0.00 | 0.00 | 0.00 | NA |
| Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | NA |
| Net Cash from Investing Activities | NA | -2.33 | -1.12 | -4.59 | NA |
Uses of Funds
| 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|---|
| Issuance (Repurchase) of Capital Stock | NA | 71.68 | 0.00 | 0.00 | NA |
| Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | NA |
| Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | NA |
| Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | NA |
| Other Financing Activities | NA | 0.00 | 41.43 | 133.60 | NA |
| Net Cash from Financing Activities | NA | 71.68 | 41.43 | 133.60 | NA |
| Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | NA |
| Net Change In Cash & Equivalents | NA | -51.06 | 0.00 | 0.00 | NA |
| Cash at Beginning of Period | NA | 277.92 | 0.00 | 0.00 | NA |
| Cash at End of Period | NA | 226.86 | 0.00 | 0.00 | NA |
| Diluted Net EPS | NA | 125.48 | NA | NA | NA |